May 7th 2024
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Experts Explore Landscape Advancements for Cancer Immunotherapy Month
June 23rd 2021As numerous approvals across cancer settings and emerging approaches are explored in clinical research, new findings presented at the 2021 American Society of Clinical Oncology Annual Meeting in June continue to encourage investigators.
Read More
Further Research Needed to Support Use of Checkpoint Inhibitors in Locally Advanced HNSCC
May 6th 2021Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.
Read More
Largest Study of Black Patients With Cancer Aims to Show Better Responses to Immunotherapy
April 21st 2021The first large study of Black patients receiving immune checkpoint inhibitors is underway to uncover differences in response to immunotherapy in Black patients compared with White patients.
Read More
FDA Advises on Termination of ERC1671 Clinical Trial in Recurrent Glioblastoma
April 7th 2021The FDA has issued a letter to the developer of the immunotherapy vaccine, ERC1671, recommending that the phase 2 clinical trial of ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, and cyclophosphamide for the treatment of glioblastoma be terminated.
Read More
Machines and Patient Power Move Biomarker Discoveries Forward
March 27th 2021The biggest unanswered question in biomarker development for cancer is how to determine which patients will respond to targeted therapy or immunotherapy. Investigators around the world are trying to answer this through clinical trials and data mining, in addition to finding new tools to add to the mix.
Read More
Investigational Anti-Clever-1 Antibody Shows Early Activity in Advanced Solid Tumors
March 22nd 2021Bexmarilimab, a novel anti-Clever-1 antibody, has shown signals of significant efficacy as a treatment of patients with 10 hard-to-treat solid tumors, according to an update from the phase 1/2 MATINS clinical trial.
Read More
Immunotherapy and Targeted Therapy Triplet Active in Microsatellite Stable mCRC
January 27th 2021The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.
Read More
Practice Gaps for Immunotherapy Identified in Community Oncology Centers
December 14th 2020Only 61% of patients completed therapy fully with checkpoint inhibition as planned, while treatment was delayed or discontinued in 22% due to immune-related adverse events, according to findings from a quality improvement research study conducted by the Association of Community Cancer Centers.
Read More
Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC
November 21st 2020During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
Read More
Novel Small Molecule +/- Pembrolizumab Induces Responses in Various Solid Tumors
November 17th 2020The oral small molecule FLX475 demonstrated promise when administered either alone or in combination with the immune checkpoint inhibitor pembrolizumab in multiple solid tumors, according to findings from a phase 1/2 dose-escalation and expansion study.
Read More
TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential
November 7th 2020Tumor mutational burden has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. However, use of this biomarker has been challenged along the way with various criticisms of validity and routine use.
Read More
Immunotherapy Combinations Appear Efficacious in Long-Term Follow-up of Advanced RCC
October 30th 2020In an interview with Targeted Oncology, Laurence Albiges, MD, PhD, discussed the updated findings for the combination of nivolumab and ipilimumab as treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma.
Read More
An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.
Read More
Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.
Read More
iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors
June 22nd 2020“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."
Read More
The study showed that the development of immune-related adverse events in advanced solid tumors was positively correlated with improved progression-free survival and overall survival in a retrospective analysis, which also showed that Caucasian patients developed immune-related adverse events more frequently than African American patients.
Read More
“We don’t have a good understanding of why some patients have a robust response to immunotherapy and others do not. That’s important, not only in terms of selecting patients but also in terms of the therapy approach. This is one reason why clinical trials are incredibly important.”
Read More